<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04167449</url>
  </required_header>
  <id_info>
    <org_study_id>EP-1006</org_study_id>
    <nct_id>NCT04167449</nct_id>
  </id_info>
  <brief_title>Effects of Korean Red Ginseng Extract on Electrical Brain Activity in Elderly Subjects</brief_title>
  <official_title>Effects of Korean Red Ginseng Extract on Electrical Brain Activity in Elderly Subjects. A Prospective, Randomized, Double Blind, Placebo-controlled, 3-armed Cross-over Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EuroPharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EuroPharma, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, randomized, double blind, placebo-controlled study to determine if a&#xD;
      hydroponically-cultivated red ginseng preparation is superior to conventionally grown ginseng&#xD;
      and placebo for positively affecting electrical activity of the brain during performance of&#xD;
      various cognitive tasks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Actual">May 1, 2020</completion_date>
  <primary_completion_date type="Actual">March 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in baseline electrical activity of the brain as measured by Quantitative Electroencephalogram for the hydroponic Korean red ginseng preparation versus conventional ginseng and placebo</measure>
    <time_frame>Four weeks</time_frame>
    <description>Responses of electric brain activity as spectral power in 17 different brain regions within 6 specially defined frequency ranges (delta, theta, alpha1, alpha2, beta1 and beta2) during cognitive performance: d2-test for attention (d2-Test).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in baseline electrical activity of the brain as measured by Quantitative Electroencephalogram for the hydroponic Korean red ginseng preparation versus conventional ginseng and placebo</measure>
    <time_frame>Four weeks</time_frame>
    <description>Responses of electric brain activity as spectral power in 17 different brain regions within 6 specially defined frequency ranges (delta, theta, alpha1, alpha2, beta1 and beta2) during cognitive performance: memory test (ME-Test).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in baseline electrical activity of the brain as measured by Quantitative Electroencephalogram for the hydroponic Korean red ginseng preparation versus conventional ginseng and placebo</measure>
    <time_frame>Four weeks</time_frame>
    <description>Responses of electric brain activity as spectral power in 17 different brain regions within 6 specially defined frequency ranges (delta, theta, alpha1, alpha2, beta1 and beta2) during cognitive performance: concentration-performance-test with financial reward (CPT-Test).</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Brain Waves</condition>
  <arm_group>
    <arm_group_label>Hydroponic Red Ginseng</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional White Ginseng</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>HRG80 Hydroponic Red Ginseng</intervention_name>
    <description>Powdered root preparation of Panax ginseng standardized to 31.7 mg total ginsenosides</description>
    <arm_group_label>Hydroponic Red Ginseng</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Conventional White Ginseng</intervention_name>
    <description>Powdered root preparation of Panax ginseng standardized to 9.8 mg total ginsenosides</description>
    <arm_group_label>Conventional White Ginseng</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Visually identical placebo capsule containing rice flour</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject must be capable of giving informed consent.&#xD;
&#xD;
          -  Acceptance of written consent to participate in the study after instruction in written&#xD;
             and oral form (informed consent).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with acute or chronic diseases that are relevant to the study and asked for&#xD;
             by the study staff are excluded:&#xD;
&#xD;
          -  Acute or chronic disease with an impact on the study, which becomes obvious by case&#xD;
             history or clinical examination.&#xD;
&#xD;
          -  Clinically relevant allergic symptoms.&#xD;
&#xD;
          -  Detection of alcohol at the time of initial examination (day SC) or on any study&#xD;
             (positive alcohol test) or by case history.&#xD;
&#xD;
          -  Consumption of clinically relevant medication during last 14 days before and during&#xD;
             the active study period based on the notification of the subject or his case history.&#xD;
&#xD;
          -  Consumption of medication with primarily central action (i.e. psychotropic drugs or&#xD;
             centrally acting antihypertensive drugs). Known intolerance / hypersensitivity&#xD;
             (allergy) to plant derived extracts or any of the ingredients of the investigational&#xD;
             product (anamnestic).&#xD;
&#xD;
          -  Consumption of unusual quantities or misuse of coffee (more than 4 cups a day), tea&#xD;
             (more than 4 cups a day).&#xD;
&#xD;
          -  Smoking in the study center on study days A, B, C and D.&#xD;
&#xD;
          -  Participation in another clinical trial within the last 60 days.&#xD;
&#xD;
          -  Bad compliance.&#xD;
&#xD;
          -  Cancellation of informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wilfried Dimpfel, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NeuroCode AG</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Labors of NeuroCode AG</name>
      <address>
        <city>Wetzlar</city>
        <zip>D-35578</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 15, 2019</study_first_submitted>
  <study_first_submitted_qc>November 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2019</study_first_posted>
  <last_update_submitted>February 15, 2021</last_update_submitted>
  <last_update_submitted_qc>February 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

